A
Andrea Khong
Researcher at University of Western Australia
Publications - 16
Citations - 1093
Andrea Khong is an academic researcher from University of Western Australia. The author has contributed to research in topics: Immune system & Immunotherapy. The author has an hindex of 12, co-authored 16 publications receiving 942 citations. Previous affiliations of Andrea Khong include Murdoch University & Lions Eye Institute.
Papers
More filters
Journal ArticleDOI
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
TL;DR: The literature on the immunogenic effects of platinum is reviewed, the clinical advances using platinum as a cytotoxic compound with immune adjuvant properties are summarized, the limitations to these studies are discussed, and the gaps in the understanding of the immunologic effects of these drugs are discussed.
Journal ArticleDOI
Innate immunity defines the capacity of antiviral T cells to limit persistent infection
Daniel M. Andrews,Marie J Estcourt,Marie J Estcourt,Christopher E. Andoniou,Christopher E. Andoniou,Matthew E. Wikstrom,Matthew E. Wikstrom,Andrea Khong,Andrea Khong,Valentina Voigt,Valentina Voigt,Peter Fleming,Peter Fleming,Hyacinth Tabarias,Hyacinth Tabarias,Geoffrey R. Hill,Robbert van der Most,Anthony A. Scalzo,Anthony A. Scalzo,Mark J. Smyth,Mariapia A. Degli-Esposti,Mariapia A. Degli-Esposti +21 more
TL;DR: It is shown that NK cells negatively regulate the duration and effectiveness of virus-specific CD4+ and CD8+ T cell responses by limiting exposure of T cells to infected antigen-presenting cells, which impacts the quality of Tcell responses and the ability to limit viral persistence.
Journal ArticleDOI
Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity
W. Joost Lesterhuis,W. Joost Lesterhuis,Joanne Salmons,Anna K. Nowak,Anna K. Nowak,Esdy N. Rozali,Andrea Khong,Ian M. Dick,Julie A. Harken,Bruce W. S. Robinson,Bruce W. S. Robinson,Richard A. Lake +11 more
TL;DR: Gemcitabine chemotherapy in combination with CTLA-4 blockade results in the induction of a potent anti-tumor immune response and the results show that immune checkpoint blockade and cytotoxic chemotherapy can have a synergistic effect in the treatment of cancer.
Journal ArticleDOI
The use of agonistic anti-CD40 therapy in treatments for cancer
TL;DR: The mechanisms of action of agonistic anti-CD40 are summarized, the use of mouse models to investigate its effects and combinations with other therapies in vivo, and current clinical trials combining humanized anti- CD40 antibody with chemotherapy and/or other immunotherapies are summarized.
Journal ArticleDOI
Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.
Alison M. McDonnell,Willem Joost Lesterhuis,Andrea Khong,Anna K. Nowak,Anna K. Nowak,Richard A. Lake,Andrew J. Currie,Bruce W. S. Robinson +7 more
TL;DR: It is demonstrated that DC cross‐presentation within the tumor microenvironment is defective, but can be reversed by chemotherapy, which has important implications for anticancer therapy, particularly regarding the use of immunotherapy in conjunction with cytotoxic chemotherapy.